Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a
variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and
safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.